ALNYLAM PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M |
| Cost of revenue | $677.2M | $306.5M | $268.2M | $140.2M | $115.0M |
| Selling, general & administrative | $1.2B | $975.5M | $795.6M | $770.7M | $620.6M |
| Research and development | $1.3B | $1.1B | $1.0B | $883.0M | $792.2M |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M |
| Interest expense | $252.6M | $141.9M | $121.2M | $156.0M | $143.0M |
| Pretax income | $323.2M | -$377.4M | -$433.5M | -$1.1B | -$852.1M |
| Income tax expense | $9.4M | -$99.2M | $6.7M | $4.2M | $680,000 |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.1B | -$852.8M |
| Balance Sheet | |||||
| Cash and equivalents | $1.7B | $966.4M | $812.7M | $866.4M | $820.0M |
| Current assets | $4.1B | $3.3B | $3.0B | $2.7B | $2.8B |
| Total assets | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B |
| Current liabilities | $1.5B | $1.2B | $967.8M | $767.9M | $695.7M |
| Total liabilities | $4.2B | $4.2B | $4.1B | $3.7B | $3.1B |
| Stockholders' equity | $789.2M | $67.1M | -$220.6M | -$158.2M | $588.2M |
| Cash Flow Statement | |||||
| Cash from operations | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M |
| Depreciation and amortization | $55.7M | $56.7M | $54.1M | $44.5M | $47.6M |
| Stock-based compensation | $348.2M | $272.1M | $221.7M | $230.6M | $165.7M |
| Capital expenditure | $58.7M | $34.3M | $62.2M | $72.1M | $76.4M |
| Free cash flow | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M |
Shares outstanding 133.5M · Free float 99.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.